Pancreatic Cancer

>

Latest News

A total of 34 patients were included in the efficacy analysis; all received 320 mg of atebimetinib once daily plus 1000 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel.
Atebimetinib Plus SOC Chemo Improves Survival/Safety in 1L PDAC

September 25th 2025

Atebimetinib with gemcitabine and nab-paclitaxel achieved a 9-month OS and PFS of 86% and 53%, respectively, in patients with pancreatic cancer in frontline settings.

analysis of biomarkers associated with outcomes from the trial was presented.3 The biomarker analysis demonstrated that intratumoral myeloid cells and T cells were activated in responding patients.
Mitazalimab/Chemo Yields Promising Survival/Responses in Untreated PDAC

September 22nd 2025

Favorable survival outcomes were identified, overall, in the wild-type and GOF groups vs the non-GOF group.
P53 Mutations May Reveal Viability of Different Pancreatic Cancer Therapies

September 20th 2025

An independent data monitoring committee recommended the continuation of the phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in PDAC in August 2025.
ELI-002 7P Elicits T Cell Responses in Mutant KRAS-Driven Tumors

September 18th 2025

After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.
mFOLFIRINOX/S-IROX Does Not Show Superiority to SOC in Pancreatic Cancer

August 22nd 2025

Video Series
Video Interviews
Podcasts
A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.
Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.
Experts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.
Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.
Oncology Peer Review On-The-Go
Latest CME Events & Activities

More News